Literature DB >> 18657422

Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.

Sylvain Lebreton1, Janis Jaunbergs, Michael G Roth, Deborah A Ferguson, Jef K De Brabander.   

Abstract

The natural product salicylihalamide is a potent inhibitor of the Vacuolar ATPase (V-ATPase), a potential target for antitumor chemotherapy. We generated salicylihalamide-resistant tumor cell lines typified by an overexpansion of lysosomal organelles. We also found that many tumor cell lines upregulate tissue-specific plasmalemmal V-ATPases, and hypothesize that tumors that derive their energy from glycolysis rely on these isoforms to maintain a neutral cytosolic pH. To further validate the potential of V-ATPase inhibitors as leads for cancer chemotherapy, we developed a multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657422      PMCID: PMC2593418          DOI: 10.1016/j.bmcl.2008.07.003

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  35 in total

1.  The development of L2X2Ru=CHR olefin metathesis catalysts: an organometallic success story.

Authors:  T M Trnka; R H Grubbs
Journal:  Acc Chem Res       Date:  2001-01       Impact factor: 22.384

2.  A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles.

Authors:  S Paglin; T Hollister; T Delohery; N Hackett; M McMahill; E Sphicas; D Domingo; J Yahalom
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

Review 3.  Natural products as sources of new drugs over the period 1981-2002.

Authors:  David J Newman; Gordon M Cragg; Kenneth M Snader
Journal:  J Nat Prod       Date:  2003-07       Impact factor: 4.050

Review 4.  Plasmalemmal vacuolar-type H+-ATPase in cancer biology.

Authors:  Souad R Sennoune; Defeng Luo; Raul Martínez-Zaguilán
Journal:  Cell Biochem Biophys       Date:  2004       Impact factor: 2.194

5.  Formal total syntheses of the (-)-salicylihalamides A and B from D-glucose and L-rhamnose.

Authors:  Torsten Haack; KyoungLang Haack; Wibke E Diederich; Burchelle Blackman; Subho Roy; Srinivas Pusuluri; Gunda I Georg
Journal:  J Org Chem       Date:  2005-09-16       Impact factor: 4.354

Review 6.  Novel marine and microbial natural product inhibitors of vacuolar ATPase.

Authors:  John A Beutler; Tawnya C McKee
Journal:  Curr Med Chem       Date:  2003-05       Impact factor: 4.530

7.  Total synthesis and initial structure-function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds.

Authors:  Yusheng Wu; Xibin Liao; Ruifang Wang; Xiao-Song Xie; Jef K De Brabander
Journal:  J Am Chem Soc       Date:  2002-04-03       Impact factor: 15.419

8.  Total synthesis of (-)-salicylihalamide A.

Authors:  B B Snider; F Song
Journal:  Org Lett       Date:  2001-06-14       Impact factor: 6.005

9.  Salicylihalamide A inhibits the V0 sector of the V-ATPase through a mechanism distinct from bafilomycin A1.

Authors:  Xiao-Song Xie; David Padron; Xibin Liao; Jin Wang; Michael G Roth; Jef K De Brabander
Journal:  J Biol Chem       Date:  2004-03-03       Impact factor: 5.157

10.  Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Authors:  Rosanna Supino; Giovanna Petrangolini; Graziella Pratesi; Monica Tortoreto; Enrica Favini; Laura Dal Bo; Patrizia Casalini; Enrico Radaelli; Anna Cleta Croce; Giovanni Bottiroli; Paola Misiano; Carlo Farina; Franco Zunino
Journal:  J Pharmacol Exp Ther       Date:  2007-10-01       Impact factor: 4.030

View more
  24 in total

1.  Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis.

Authors:  Edgardo J Toro; Jian Zuo; David A Ostrov; Dana Catalfamo; Vivian Bradaschia-Correa; Victor Arana-Chavez; Aliana R Caridad; John K Neubert; Thomas J Wronski; Shannon M Wallet; L Shannon Holliday
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

2.  Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.

Authors:  Oxana V Denisova; Sandra Söderholm; Salla Virtanen; Carina Von Schantz; Dmitrii Bychkov; Elena Vashchinkina; Jens Desloovere; Janne Tynell; Niina Ikonen; Linda L Theisen; Tuula A Nyman; Sampsa Matikainen; Olli Kallioniemi; Ilkka Julkunen; Claude P Muller; Xavier Saelens; Vladislav V Verkhusha; Denis E Kainov
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection.

Authors:  Konstantin H Müller; Gilles A Spoden; Konstanze D Scheffer; Regina Brunnhöfer; Jef K De Brabander; Martin E Maier; Luise Florin; Claude P Muller
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

4.  Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries.

Authors:  Tyler A Johnson; Johann Sohn; Yvette M Vaske; Kimberly N White; Tanya L Cohen; Helene C Vervoort; Karen Tenney; Frederick A Valeriote; Leonard F Bjeldanes; Phillip Crews
Journal:  Bioorg Med Chem       Date:  2012-05-24       Impact factor: 3.641

5.  Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition.

Authors:  Karin von Schwarzenberg; Romina M Wiedmann; Prajakta Oak; Sabine Schulz; Hans Zischka; Gerhard Wanner; Thomas Efferth; Dirk Trauner; Angelika M Vollmar
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

6.  Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway.

Authors:  Zhiqiang Wang; Shimeng Liu; Miyo Kakizaki; Yuuki Hirose; Yukiko Ishikawa; Hiromasa Funato; Masashi Yanagisawa; Yonghao Yu; Qinghua Liu
Journal:  J Biol Chem       Date:  2014-10-02       Impact factor: 5.157

7.  The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.

Authors:  Konstantin H Müller; Denis E Kainov; Karim El Bakkouri; Xavier Saelens; Jef K De Brabander; Christian Kittel; Elisabeth Samm; Claude P Muller
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

8.  Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.

Authors:  Oxana V Denisova; Laura Kakkola; Lin Feng; Jakob Stenman; Ashwini Nagaraj; Johanna Lampe; Bhagwan Yadav; Tero Aittokallio; Pasi Kaukinen; Tero Ahola; Suvi Kuivanen; Olli Vapalahti; Anu Kantele; Janne Tynell; Ilkka Julkunen; Hannimari Kallio-Kokko; Henrik Paavilainen; Veijo Hukkanen; Richard M Elliott; Jef K De Brabander; Xavier Saelens; Denis E Kainov
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

9.  Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.

Authors:  Hyun Seok Kim; Saurabh Mendiratta; Jiyeon Kim; Chad Victor Pecot; Jill E Larsen; Iryna Zubovych; Bo Yeun Seo; Jimi Kim; Banu Eskiocak; Hannah Chung; Elizabeth McMillan; Sherry Wu; Jef De Brabander; Kakajan Komurov; Jason E Toombs; Shuguang Wei; Michael Peyton; Noelle Williams; Adi F Gazdar; Bruce A Posner; Rolf A Brekken; Anil K Sood; Ralph J Deberardinis; Michael G Roth; John D Minna; Michael A White
Journal:  Cell       Date:  2013-10-24       Impact factor: 41.582

10.  Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.

Authors:  Hui-Wen Chen; Jenna Xiao Cheng; Ming-Tsan Liu; Kevin King; Ju-Yi Peng; Xin-Quan Zhang; Ching-Ho Wang; Sujan Shresta; Robert T Schooley; Yu-Tsueng Liu
Journal:  Antiviral Res       Date:  2013-06-29       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.